Search

Displaying results 1901 - 1910 of 7479 in total
  1. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. NK-1 receptors are expressed in the brainstem and nucleus tractus solitarius, which receives emetogenic signals from various stimuli...

  2. Drug

    Sodium molybdate

    go.drugbank.com/drugs/DB14496
    Approved

    Mixtures: GENERADOR DE SOLUCION INYECTABLE DE PERTECNETATO (99MTC) DE SODIO. 2-50GBQ, VINATAL DHA CAPSULA DE GELATINA BLANDA
  3. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA).

  4. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing acti...

  5. Drug

    Hydroxocobalamin

    go.drugbank.com/drugs/DB00200
    ApprovedInvestigational

    Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency.

    Mixtures: Escavite DProducts: VITAMIN B12 DEP PAN 1000UG
  6. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). … [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474]

  7. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [

  8. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. … PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders.

  9. Drug

    Histrelin

    go.drugbank.com/drugs/DB06788
    ApprovedInvestigationalWithdrawn

    [L41710] GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. … Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses.

    Synonyms: [(im-Bzl)-D-His6,Pro9-NEt]-gonadotropin releasing hormone, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide
  10. Drug

    Telotristat ethyl

    go.drugbank.com/drugs/DB12095
    Approved

    [L43367] Overexposure to serotonin can cause severe diarrhea, one of the main clinical symptoms of carcinoid syndrome. … [A252947] Neuroendocrine tumors (NET) arising from these cells can therefore secrete chemical mediators into the bloodstream to cause side effects in distant sites, a phenomenon called carcinoid syndrome